Prijeđi na sadržaj

Tahikininski receptor 1

Izvor: Wikipedija
edit
Tahikininski receptor 1
Identifikatori
SimboliTACR1; SPR; NK1R; NKIR; TAC1R
Vanjski IDOMIM: 162323 MGI: 98475 HomoloGene: 20288 IUPHAR: NK1 GeneCards: TACR1 Gene
Pregled RNK izražavanja
podaci
Ortolozi
VrstaČovekMiš
Entrez686921336
EnsemblENSG00000115353ENSMUSG00000030043
UniProtP25103Q3V353
RefSeq (mRNA)NM_001058NM_009313
RefSeq (protein)NP_001049NP_033339
Lokacija (UCSC)Chr 2:
75.13 - 75.28 Mb		Chr 6:
82.37 - 82.53 Mb
PubMed pretraga[1][2]

Tahikininski receptor 1 (TACR1, neurokininski 1 receptor, NK1R, ili receptor supstance P, SPR) je G protein spregnuti receptor koji je nađen u centralnom i perifernom nervnom sistemu. Endogeni ligand ovog receptora je supstanca P. On ima afinitet i za druge tahikinine. Protein je proizvod TACR1 gena.[1]

Osobine

[uredi | uredi kod]

Tahikinini su familija neuropeptida koji imaju zajednički hidrofobni C-terminalni region sa aminokiselinskom sekvencom Phe-X-Gly-Leu-Met-NH2, gde X predstavlja hidrofobni ostatak koji je bilo aromatičan ili beta-razgranati alifatik. N-terminalni region varira između različitih tahikinina.[2][3][4] Termin tahikinin odražava brzi početak delovanja ovih peptida u glatkim mišićima.[4] SP je najistraženiji i najpotentniji član tahikininske familije. On je undekapeptid sa aminokiselinskom sekvencom Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2.[2] SP se vezuje za sva tri tahikininska receptora, ali se najjače vezuje za NK1 receptor.[3]

Tahikininski NK1 receptor[5] sadrži 407 aminokiselina, i ima molekulsku težinu od 58 kDa.[2][6] NK1 receptor, kao i drugi tahikininski receptori, sadrži sedam hidrofobnih transmembranskih domena sa tri ekstracelularne i tri intracelularne petlje, ekstracelularnim amino-terminusom i citoplazmatičnim karboksilnim-terminusom. Petlje sadrže funkcionalna mesta, koja obuhvataju dve cisteinske aminokiseline koje formiraju disulfidni most, Asp-Arg-Tyr motiv koji je odgovoran za vezivanje arestina, i Lys/Arg-Lys/Arg-X-X-Lys/Arg sekvencu koja interaguje sa G-proteinima.[5][6]

Klinički značaj

[uredi | uredi kod]

Ovaj receptor se smatra atraktivnim ciljem za razvoj lekova sa analgetičkim i antidepresantskim svojstvima.[7][8] On je bio identifikovan kao kandidat u etiologiji manično-depresivne psihoze u jednoj studiji iz 2008.[9] Osim toga za TACR1 antagoniste je pokazano da potencijalno mogu da nađu primenu u lečenju alkoholizma.[10] Konačno, postoji mogućnost da se TACR1 antagonisti mogu koristiti kao antiemetike.[11]

Selektivni ligandi

[uredi | uredi kod]

Mnogi selektivni NK1 ligandi za su dostupni, nekoliko njih je bilo u kliničkim ispitivanjima kao antiemetici.

Agonisti

[uredi | uredi kod]
  • GR-73632 - potentan i selektivan agonist, EC50 2nM, polipeptid sa pet aminokiselina

Antagonisti

[uredi | uredi kod]

Povezano

[uredi | uredi kod]

Literatura

[uredi | uredi kod]
  1. ↑ Takeda Y, Chou KB, Takeda J, Sachais BS, Krause JE (1991). „Molecular cloning, structural characterization and functional expression of the human substance P receptor”. Biochem. Biophys. Res. Commun. 179 (3): 1232–40. DOI:10.1016/0006-291X(91)91704-G. PMID 1718267. 
  2. ↑ 2,0 2,1 2,2 Ho W. Z., Douglas S. D. (December 2004). „Substance P and neurokinin-1 receptor modulation of HIV”. Journal of Neuroimmunology 157 (1–2): 48–55. DOI:10.1016/j.jneuroim.2004.08.022. PMID 15579279. Arhivirano iz originala na datum 2009-09-01. Pristupljeno 2014-05-08. 
  3. ↑ 3,0 3,1 Page N. M. (August 2005). „New challenges in the study of the mammalian Tachykinins”. Peptides 26 (8): 1356–1368. DOI:10.1016/j.peptides.2005.03.030. PMID 16042976. 
  4. ↑ 4,0 4,1 Datar P., Srivastava S., Coutinho E., Govil G. (2004). „Substance P: Structure, Function, and Therapeutics”. Current Topics in Medicinal Chemistry 4 (1): 75–103. DOI:10.2174/1568026043451636. PMID 14754378. Arhivirano iz originala na datum 2009-09-18. Pristupljeno 2014-05-08. 
  5. ↑ 5,0 5,1 Satake H., Kawada T. (August 2006). „Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors”. Current Drug Targets 7 (8): 963–974. DOI:10.2174/138945006778019273. Arhivirano iz originala na datum 2009-09-03. Pristupljeno 2014-05-08. 
  6. ↑ 6,0 6,1 Almeida T. A., Rojo J., Nieto P. M., Hernandez M., Martin J. D., Candenas M. L. (August 2004). „Tachykinins and Tachykinins Receptors: Structure and Activity Relationships”. Current Medicinal Chemistry 11 (15): 2045–2081. PMID 15279567. 
  7. ↑ Humphrey JM (2003). „Medicinal chemistry of selective neurokinin-1 antagonists”. Current topics in medicinal chemistry 3 (12): 1423–35. DOI:10.2174/1568026033451925. PMID 12871173. 
  8. ↑ Yu YJ, Arttamangkul S, Evans CJ, Williams JT, von Zastrow M (January 2009). „Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons”. The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 29 (1): 222–33. DOI:10.1523/JNEUROSCI.4315-08.2009. PMC 2775560. PMID 19129399. 
  9. ↑ Perlis RH, Purcell S, Fagerness J, Kirby A, Petryshen TL, Fan J, Sklar P (January 2008). „Family-based association study of lithium-related and other candidate genes in bipolar disorder”. Arch. Gen. Psychiatry 65 (1): 53–61. DOI:10.1001/archgenpsychiatry.2007.15. PMID 18180429. 
  10. ↑ George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M (March 2008). „Neurokinin 1 receptor antagonism as a possible therapy for alcoholism”. Science (journal) 319 (5869): 1536–9. DOI:10.1126/science.1153813. PMID 18276852. 
  11. ↑ Jordan K (2006). „Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy”. Onkologie 29 (1-2): 39–43. DOI:10.1159/000089800. PMID 16514255. 

Dodatna literatura

[uredi | uredi kod]
  • Burcher E (1989). „The study of tachykinin receptors.”. Clin. Exp. Pharmacol. Physiol. 16 (6): 539–43. DOI:10.1111/j.1440-1681.1989.tb01602.x. PMID 2548782. 
  • Kowall NW, Quigley BJ, Krause JE, et al. (1993). „Substance P and substance P receptor histochemistry in human neurodegenerative diseases.”. Regul. Pept. 46 (1-2): 174–85. DOI:10.1016/0167-0115(93)90028-7. PMID 7692486. 
  • Patacchini R, Maggi CA (2002). „Peripheral tachykinin receptors as targets for new drugs.”. Eur. J. Pharmacol. 429 (1-3): 13–21. DOI:10.1016/S0014-2999(01)01301-2. PMID 11698023. 
  • Saito R, Takano Y, Kamiya HO (2003). „Roles of substance P and NK(1) receptor in the brainstem in the development of emesis.”. J. Pharmacol. Sci. 91 (2): 87–94. DOI:10.1254/jphs.91.87. PMID 12686752. 
  • Fong TM, Yu H, Huang RR, Strader CD (1992). „The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides.”. Biochemistry 31 (47): 11806–11. DOI:10.1021/bi00162a019. PMID 1280161. 
  • Fong TM, Huang RR, Strader CD (1993). „Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor.”. J. Biol. Chem. 267 (36): 25664–7. PMID 1281469. 
  • Fong TM, Anderson SA, Yu H, et al. (1992). „Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor.”. Mol. Pharmacol. 41 (1): 24–30. PMID 1310144. 
  • Takahashi K, Tanaka A, Hara M, Nakanishi S (1992). „The primary structure and gene organization of human substance P and neuromedin K receptors.”. Eur. J. Biochem. 204 (3): 1025–33. DOI:10.1111/j.1432-1033.1992.tb16724.x. PMID 1312928. 
  • Walsh DA, Mapp PI, Wharton J, et al. (1992). „Localisation and characterisation of substance P binding to human synovial tissue in rheumatoid arthritis.”. Ann. Rheum. Dis. 51 (3): 313–7. DOI:10.1136/ard.51.3.313. PMC 1004650. PMID 1374227. 
  • Gerard NP, Garraway LA, Eddy RL, et al. (1991). „Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones.”. Biochemistry 30 (44): 10640–6. DOI:10.1021/bi00108a006. PMID 1657150. 
  • Hopkins B, Powell SJ, Danks P, et al. (1991). „Isolation and characterisation of the human lung NK-1 receptor cDNA.”. Biochem. Biophys. Res. Commun. 180 (2): 1110–7. DOI:10.1016/S0006-291X(05)81181-7. PMID 1659396. 
  • Takeda Y, Chou KB, Takeda J, et al. (1991). „Molecular cloning, structural characterization and functional expression of the human substance P receptor.”. Biochem. Biophys. Res. Commun. 179 (3): 1232–40. DOI:10.1016/0006-291X(91)91704-G. PMID 1718267. 
  • Giuliani S, Barbanti G, Turini D, et al. (1992). „NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype.”. Eur. J. Pharmacol. 203 (3): 365–70. DOI:10.1016/0014-2999(91)90892-T. PMID 1723045. 
  • Ichinose H, Katoh S, Sueoka T, et al. (1991). „Cloning and sequencing of cDNA encoding human sepiapterin reductase--an enzyme involved in tetrahydrobiopterin biosynthesis.”. Biochem. Biophys. Res. Commun. 179 (1): 183–9. DOI:10.1016/0006-291X(91)91352-D. PMID 1883349. 
  • Thöny B, Heizmann CW, Mattei MG (1995). „Human GTP-cyclohydrolase I gene and sepiapterin reductase gene map to region 14q21-q22 and 2p14-p12, respectively, by in situ hybridization.”. Genomics 26 (1): 168–70. DOI:10.1016/0888-7543(95)80101-Q. PMID 7782081. 
  • Fong TM, Cascieri MA, Yu H, et al. (1993). „Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345.”. Nature 362 (6418): 350–3. DOI:10.1038/362350a0. PMID 8384323. 
  • Derocq JM, Ségui M, Blazy C, et al. (1997). „Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists.”. FEBS Lett. 399 (3): 321–5. DOI:10.1016/S0014-5793(96)01346-4. PMID 8985172. 
  • De Felipe C, Herrero JF, O'Brien JA, et al. (1998). „Altered nociception, analgesia and aggression in mice lacking the receptor for substance P.”. Nature 392 (6674): 394–7. DOI:10.1038/32904. PMID 9537323. 

Spoljašnje veze

[uredi | uredi kod]
Izvor: https://sh.wikipedia.org/w/index.php?title=Tahikininski_receptor_1&oldid=42173832